These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36029708)

  • 21. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese.
    Chan KH; Tsang KL; Ho PW; Tse CT; Kwan JS; Ho JW; Chu AC; Chang RS; Ho SL
    Clin Neurol Neurosurg; 2011 Oct; 113(8):617-22. PubMed ID: 21621913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses.
    Sumelahti ML; Tienari PJ; Hakama M; Wikström J
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):25-8. PubMed ID: 12486261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic inertia in relapsing-remitting multiple sclerosis.
    Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
    Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
    Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA
    Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in symptoms of depression between females and males with relapsing-remitting multiple sclerosis.
    Mayo CD; Lacey C; Gawryluk JR;
    Mult Scler Relat Disord; 2021 Jun; 51():102884. PubMed ID: 33799287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapsing neuromyelitis optica and relapsing-remitting multiple sclerosis: differentiation at diffusion-tensor MR imaging of corpus callosum.
    Yu CS; Zhu CZ; Li KC; Xuan Y; Qin W; Sun H; Chan P
    Radiology; 2007 Jul; 244(1):249-56. PubMed ID: 17522347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002.
    Tanaka K; Kujuro Y; Suzuki S; Tanahashi N; Hamada J; Nogawa S; Suzuki N
    Intern Med; 2005 Jun; 44(6):560-6. PubMed ID: 16020880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of miR-125a-5p and miR-218-5p in Peripheral Blood Mononuclear Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
    Mosarrezaii Aghdam A; Rezaei S; Zarza Nalivan F; Babaie F; Amiri Nikpour MR; Torkamandi S
    Immunol Invest; 2022 Jul; 51(5):1149-1161. PubMed ID: 33866949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
    Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
    J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
    Rojas JI; Patrucco L; Alonso R; Garcea O; Deri N; Carnero Contentti E; Lopez PA; Pettinicchi JP; Caride A; Cristiano E
    Mult Scler; 2021 Apr; 27(4):579-584. PubMed ID: 32484381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relation between menarche and the age of first symptoms in a multiple sclerosis cohort.
    Sloka JS; Pryse-Phillips WE; Stefanelli M
    Mult Scler; 2006 Jun; 12(3):333-9. PubMed ID: 16764348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
    Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum 25(OH) vitamin D level in Relapsing-Remitting Multiple Sclerosis and clinically isolated syndrome groups.
    Küçük A; Bir LS; Tekin S; Demir S
    Horm Mol Biol Clin Investig; 2022 Sep; 43(3):281-288. PubMed ID: 35405046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Employment among patients with multiple sclerosis-a population study.
    Bøe Lunde HM; Telstad W; Grytten N; Kyte L; Aarseth J; Myhr KM; Bø L
    PLoS One; 2014; 9(7):e103317. PubMed ID: 25054972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.